Gainers & Losers: 10 stocks that moved the most on October 6

On the sectoral front, except IT, FMCG, pharma and energy other indices ended in the green. BSE Midcap and Smallcap indices rose 0.5 percent each.

Buy Lupin; target of Rs 1085: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1085 in its research report dated September 30, 2020.

Perrigo’s pain is a windfall for Cipla, Lupin

This recall of Albuterol product by Perrigo has an immediate positive impact on the sales of similar respiratory products by competitors such as Cipla and Lupin

Lupin shares hit 52-week high, Cipla shares jump 6% after Perrigo recalls albuterol sulfate

Both stocks attracted traction after the Irish pharma company Perrigo voluntarily recalled albuterol sulfate inhalation aerosols over concerns that some may not dispense properly due to clogging.

Buy Lupin; target of Rs 1130: Motilal Oswal

Motilal Oswal is bullish on Lupin recommended buy rating on the stock with a target price of Rs 1130 in its research report dated August 25, 2020.

Buy Lupin; target of Rs 1085: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1085 in its research report dated August 25, 2020.

Lupin: At the inflection point for complex generics

The traction in complex generic products and the restructuring initiatives can accelerate earnings growth for Lupin

Lupin share price rises 5% on US FDA approval

The generic Albuterol Sulphate MDI will be manufactured at its Indore (Unit III) facility in India.

Lupin shars slips 2% after Investec retains 'sell' but raises target

Investec raised target on lupin to Rs 815 from Rs 665 per share.

Buy Lupin; target of Rs 979; KRChoksey

KRChoksey is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 979 in its research report dated August 11, 2020.

Buy Lupin; target of Rs 1015: Motilal Oswal

Motilal Oswal is bullish on Lupin recommended buy rating on the stock with a target price of Rs 1015 in its research report dated August 08, 2020.

Hold Lupin; target of Rs 905: Emkay Global Financial

Emkay Global Financial recommended hold rating on Lupin with a target price of Rs 905 in its research report dated August 08, 2020.

Buy Lupin; target of Rs 980: HDFC Securities

HDFC Securities is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 980 in its research report dated August 10, 2020.

Lupin first company to shift manufacturing of some drugs from India to US after Trump’s ‘Buy American’ order

CEO Vinita Gupta does not name the drugs. Analysts say move will not have much effect on Indian pharma sector. Gupta says US business was down 26 percent in Q1FY21 Q-o-Q. Efforts under way to bring Metformin back into the market within Q2FY21.

Buy Lupin; target of Rs 1030: ICICI Direct

ICICI Direct is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1030 in its research report dated August 09, 2020.

Lupin: Execution for US portfolio a key monitorable

Lupin's guidance for the portfolio rollout in the US market is encouraging. New launches and an improving market share in Levothyroxine are expected to help tide over structural pricing erosion in the near to medium term

Lupin Consolidated June 2020 Net Sales at Rs 3,527.86 crore, down 20.15% Y-o-Y

Lupin Standalone June 2020 Net Sales at Rs 2,695.08 crore, down 8.36% Y-o-Y

Sell Lupin; target of Rs 753: Dolat Capital

Dolat Capital is bearish on Lupin has recommended sell rating on the stock with a target price of Rs 753 in its research report dated August 08, 2020.

Lupin, Sun Pharma recall drugs in the US market

The Mumbai-based drug maker Lupin is recalling 11,688 bottles of Lisinopril tablets USP, 10 mg, which is used to treat high blood pressure, in the US market, as per the latest Enforcement Report by the US health regulator.

Buy Lupin; target of Rs 1001: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1001 in its research report dated August 08, 2020.

Hold Lupin; target of Rs 965: Sharekhan

Sharekhan recommended Hold rating on Lupin with a target price of Rs 965 in its research report dated August 07, 2020.

Lupin shares fall 6% after Q1 net profit falls 60% YoY fall

Lupin's Q1FY21 net profit from continuing operations stood at Rs 106.9 crore against Rs 264.7 crore in Q1FY20, the company said on August 6.

Lupin launches COVID-19 drug Favipiravir in India at Rs 49 per tablet

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.

Lupin gets USFDA nod for generic diabetes drug

The Mumbai-based company has received a tentative approval from the US Food and Drug Administration (USFDA) for its Empagliflozin tablets, in strengths of 10 mg and 25 mg, Lupin said in a statement.